M

Moderna

Develops mRNA-based medicines for health

Head of Analytical Development

Full-TimeUpdated on 10/22/2026
$272.2k - $490.1k+ Annual discretionary bonus + Other incentive compensation + Equity award
Expert
PhD
Norwood, MA, USA
In Person100% onsite in Norwood, Massachusetts.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A Ph.D. in Analytical Chemistry, Organic Chemistry, Biochemistry, Pharmaceutical Sciences, Chemistry, Chemical Engineering, Biochemical Engineering, or a related scientific discipline, with 18 or more years of relevant industry experience, including significant executive-level leadership experience in analytical development for biologics, vaccines, nucleic-acid-based medicines, or other advanced therapeutic modalities.
  • Demonstrated experience leading multidisciplinary technical organizations and influencing across matrixed CMC organizations, with direct accountability for analytical strategy, method development, product characterization, technical transfer, regulatory support, external partner oversight, and lifecycle management.
  • Willingness to relocate to or be based in the Norwood, Massachusetts area.
Responsibilities
  • Lead the Analytical Development organization as functional head, setting the function’s vision, strategy, priorities, operating model, technical standards, governance, resource agenda, and talent strategy.
  • Own end-to-end analytical development strategy across the product lifecycle, including early development, pivotal-enabling and late-stage development, PPQ/BLA-enabling activities, commercialization, post-approval changes, and lifecycle management.
  • Provide strategic and technical leadership across Analytical Development sub-functions, including Analytical Sciences, PhysChem method development, product characterization, microbiology, potency assurance and bioassay development, analytical program leadership, clinical stability, and analytical regulatory execution.
  • Ensure phase-appropriate analytical method development, qualification, validation readiness, clinical method transfer, troubleshooting, continued clinical method performance monitoring, and lifecycle management for mRNA-based products and other advanced therapeutic modalities.
  • Set analytical control strategies for programs, platforms, and synthetic raw materials, including specifications, critical quality attribute and potential critical quality attribute understanding, comparability strategy, reference material strategy, impurity and purity assessment, material qualification, shelf-life and retest strategy, and analytical risk management.
  • Drive product, process, and material understanding through fit-for-purpose characterization strategies for RNA, lipid nanoparticles, drug product, DNA, enzymes, lipids, synthetic raw materials, and emerging modalities, supporting process development, comparability, regulatory filings, and lifecycle decisions.
  • Provide technical analytical leadership for regulatory strategy and execution, including analytical sections of IND/IMPD/BLA/MAA submissions, comparability protocols and reports, specification justifications, stability packages, impurity justifications, briefing books, and responses to health authority questions.
  • Establish governance forums, decision frameworks, risk escalation pathways, and ways of working to create clear ownership across Analytical Development and partner functions while improving the speed, quality, and consistency of technical decisions.
  • Partner with CMC Product Leads, Process Development, ATO/AST, QC, Quality, Manufacturing, MS&T, Regulatory CMC, Supply Chain, Procurement, Legal/IP, and external partners to align priorities, resources, timelines, technical risks, intellectual property considerations, and program deliverables.
  • Ensure successful transfer and deployment of analytical methods into clinical testing, QC, manufacturing, and CDMO networks, with accountability for method readiness, transfer packages, control strategy, global network harmonization, and inspection readiness.
  • Provide analytical technical leadership for investigations involving method performance, unexpected release or stability results, impurities, or comparability, in partnership with QC, Quality, and Process Development.
  • Identify, evaluate, and implement new analytical technologies, automation, digital tools, high-throughput approaches, data science, and AI-enabled workflows to improve analytical robustness, process understanding, speed, scalability, knowledge management, and productivity.
  • Represent Moderna externally through scientific conferences, technical forums, regulatory and scientific workshops, and industry consortia; shape external dialogue, build strategic networks, benchmark emerging practices, and translate external learning into the company’s analytical strategy and capability roadmap.
  • Build and develop a high-performing leadership team by strengthening the team-lead layer, clarifying accountabilities, coaching emerging leaders, creating succession depth, and building critical technical capabilities across analytical development.
  • Manage functional resourcing, portfolio prioritization, budget tradeoffs, workforce planning, external spend, and organizational capability building to meet sustained portfolio demand, strategic platform needs, and evolving business priorities.
  • Foster a culture of scientific excellence, accountability, collaboration, enterprise thinking, regulatory rigor, and continuous improvement.
  • Create and articulate an organizational and enterprise-wide vision; analyze data from varied sources to support decisions and align others with organizational strategy; develop innovative ideas; and balance the need for change with achievable implementation plans.
  • Set clear and challenging goals, drive improved performance and results, adapt to ambiguity and uncertainty, assess risks using data and input, and make transparent, consistent decisions in the organization’s best interest.
  • Attract and recruit talent, motivate the team, delegate effectively, manage performance, develop others, persevere through challenges, lead by example, and promote continuous improvement.
  • Build relationships, communicate clearly and persuasively, inspire trust and followership, support the success of the team, and create a shared sense of purpose.
  • Integrate economic, societal, and environmental factors into strategy; incorporate stakeholder viewpoints; pursue sustainable innovation and business models; and establish sustainability goals and investments.
Desired Qualifications
  • Proven ability to lead an Analytical Development function at enterprise scale, with accountability for strategy, execution, organizational design, governance, talent development, resource planning, and cross-functional delivery.
  • Deep scientific and technical expertise across analytical development domains relevant to mRNA and advanced modality products, including separation sciences, nucleic acid analytics, lipid nanoparticle and particle characterization, residual impurity testing, compendial methods, bioassays, potency, microbiological methods, reference materials, synthetic raw material analytics, impurity characterization, and emerging analytical technologies.
  • Strong understanding of CMC development from early clinical stages through commercialization, including phase-appropriate analytical expectations, method lifecycle, analytical control strategy, specifications, comparability, and global regulatory submission requirements.
  • Demonstrated leadership in establishing analytical playbooks, platform methods, technical standards, governance forums, risk frameworks, and decision-making mechanisms that improve speed, consistency, and quality across a broad development portfolio.
  • Demonstrated success partnering with QC, ATO/AST, Quality, Process Development, Manufacturing, MS&T, Supply Chain, Regulatory CMC, Procurement, Legal/IP, program leadership, and external CDMO and testing partners to align technical strategy and execution across development and commercial networks.
  • Demonstrated leadership of analytical strategy and deliverables for IND/IMPD and BLA/MAA submissions, health authority interactions, and post-approval lifecycle management.
  • Strong external scientific presence and influence, including representing an organization in conferences, technical forums, regulatory or scientific workshops, and industry consortia; shaping external standards, benchmarking best practices, and bringing external innovation into internal strategy.
  • Strong record of building leadership benches, mentoring senior scientists and people leaders, managing complex organizational change, and creating growth pathways for technical and managerial talent.
  • Ability to make clear, risk-based decisions in ambiguous situations, balance speed with scientific and regulatory rigor, and communicate complex analytical strategies to technical, executive, and cross-functional audiences.
  • Experience advancing analytical innovation, automation, digital systems, data science, AI-enabled workflows, high-throughput analytical approaches, and platform scalability to improve productivity and quality.
  • Excellent communication, stakeholder management, enterprise leadership, and organizational influence skills, with the ability to lead through direct authority and matrixed accountability.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.

CNBC
Oct 14th, 2026
Merck CEO expects Moderna cancer vaccine's six-week production time to shorten

Merck chief executive officer Rob Davis expects the company's personalised cancer vaccine with Moderna to become faster to make over time. He told CNBC the current timeline is six weeks, from sequencing a patient's tumour to delivering the shot to the hospital. "I do think over time you're going to see that timeline shortened," Davis said. For now, the focus is on readying supply and the market. The vaccine targets the mutations in each patient's tumour and is paired with Merck's immunotherapy Keytruda. In August, the companies released positive initial late-stage data in melanoma patients. Trials are also under way in lung, bladder, and kidney cancers. Davis spoke as Merck opened its 120,000-square-foot research facility, Advance, in West Point, Pennsylvania.